SCHEMBL972909

SCHEMBL972909

Cc1nc(-c2ccccc2)n2c1c(=O)[nH]c1ccc(Cl)cc12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 4/20 0.53
PDE2A O00408 1/20 0.48
PDE6D O43924 1/20 0.48
PDE8A O60658 1/20 0.48
PDE5A O76074 1/20 0.48
PDE9A O76083 1/20 0.48
PDE8B O95263 1/20 0.48
PDE6A P16499 1/20 0.48
PDE6G P18545 1/20 0.48
PDE4A P27815 1/20 0.48
PDE6B P35913 1/20 0.48
PDE6C P51160 1/20 0.48
PDE1A P54750 1/20 0.48
PDE1B Q01064 1/20 0.48
PDE4B Q07343 1/20 0.48
PDE4C Q08493 1/20 0.48
PDE4D Q08499 1/20 0.48
PDE3B Q13370 1/20 0.48
PDE7A Q13946 1/20 0.48
PDE6H Q13956 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3591362 0.83 PDE2A (0.46) ADORA3PDE2APDE6DPDE8APDE5A
SCHEMBL3595824 0.78 PDE2A (0.53) ADORA3PDE2APDE6DPDE8APDE5A
SCHEMBL968422 0.77 RAB9A (0.60) PDE2APDE10AKDM4EMEN1KMT2A
SCHEMBL972907 0.74 CSF1R (0.43) ADORA3PDE2APDE6DPDE8APDE5A
SCHEMBL971047 0.74 RAB9A (0.58) PDE2APDE10AKDM4EMEN1KMT2A
SCHEMBL3598766 0.74 KDM4E (0.42) PDE2APDE6DPDE8APDE5APDE9A
SCHEMBL3595215 0.73 TLR8 (0.46) PDE2APDE6DPDE8APDE5APDE9A
SCHEMBL3591869 0.73 PDE2A (0.41) PDE2APDE6DPDE8APDE5APDE9A
SCHEMBL3598874 0.71 PDE9A (0.50) ADORA3PDE2APDE6DPDE8APDE5A
SCHEMBL3491789 0.71 TLR8 (0.38) ADORA3PDE2APDE6DPDE8APDE5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7875618-B2 8-chloro-3,4-dimethyl-1-(2- methylphenyl)imidazo[1,5- a]quinoxaline; inhibitors of phosphodiesterase 10; for treatment of central nervous system disorders (cognitive deficits, social phobia, reduced vigilance, obesity and psychosis) WYETH (US) 2011-01-25 US disclosed
EP-2225248-A1 ARYL AND HETEROARYL FUSED IMIDAZO[1,5-A]PYRAZINES AS INHIBITORS OF PHOSPHODIESTERASE 10 Wyeth LLC (US) 2010-09-08 EP disclosed
WO-2009070584-A1 ARYL AND HETEROARYL FUSED IMIDAZO[1,5-A]PYRAZINES AS INHIBITORS OF PHOSPHODIESTERASE 10 WYETH (US) 2009-06-04 WO disclosed
US-20090143367-A1 ARYL AND HETEROARYL FUSED IMIDAZO[1,5-a]PYRAZINES AS INHIBITORS OF PHOSPHODIESTERASE 10 ELBION GMBH (DE) 2009-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143367-A1 ARYL AND HETEROARYL FUSED IMIDAZO[1,5-a]PYRAZINES AS INHIBITORS OF PHOSPHODIESTERASE 10 PDE12, PDE5A, PDE10A ADORA3 960/4885PDE2A 6/4885PDE6D 31/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.